Insulet Corporation (PODD)

NASDAQ
Currency in USD
310.90
+3.23(+1.05%)
Closed·
After Hours
324.90+14.00(+4.50%)
·
PODD Scorecard
Full Analysis
11 analysts have revised their earnings upwards for the upcoming period
PODD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
304.13315.49
52 wk Range
173.00329.33
Key Statistics
Edit
Prev. Close
307.67
Open
310.46
Day's Range
304.13-315.49
52 wk Range
173-329.33
Volume
908.07K
Average Volume (3m)
872.89K
1-Year Change
52.45%
Book Value / Share
18.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PODD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Insulet Corporation News & Analysis

Show more

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Insulet Corporation SWOT Analysis


Diabetes Tech Leade
Insulet's Omnipod system drives 30% worldwide growth, with Q1 2025 sales exceeding expectations and prompting upward revision of revenue guidance
Market Expansion
Explore Insulet's strategic focus on the Type 2 diabetes market, representing over 30% of new customers and offering significant growth potential
Global Reach
Delve into Insulet's international success, with recent launches in Canada and Switzerland contributing to robust growth beyond U.S. borders
Analyst Optimism
Learn about analyst price targets ranging from $266 to $360, reflecting confidence in Insulet's market position and growth prospects
Read full SWOT analysis

Insulet Corporation Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of $1.02 beat forecast by 29%; revenue grew 30% YoY to $569M, surpassing expectations
  • Gross margin improved to 71.9%, up 240 bps; stock surged 8.95% after-hours on strong results
  • FY2025 outlook: 20-23% Omnipod revenue growth; 100+ bps annual operating margin improvement targeted
  • CEO highlights leadership in automated insulin delivery; potential for growth in Type 2 diabetes market emphasized
  • Risks include supply chain disruptions, market saturation, and emerging competition in diabetes care
Last Updated: 08/05/2025, 22:34
Read Full Transcript

Compare PODD to Peers and Sector

Metrics to compare
PODD
Peers
Sector
Relationship
P/E Ratio
54.4x−3.6x−0.5x
PEG Ratio
0.81−0.030.00
Price/Book
16.4x2.6x2.6x
Price / LTM Sales
10.0x2.5x3.0x
Upside (Analyst Target)
7.5%77.9%50.5%
Fair Value Upside
Unlock−17.4%7.5%Unlock

Earnings

Latest Release
May 08, 2025
EPS / Forecast
1.02 / 0.79
Revenue / Forecast
569.00M / 543.22M
EPS Revisions
Last 90 days

Insulet (PODD) Income Statement & Profits

People Also Watch

246.65
LHX
-1.78%
164.50
STZ
+0.73%
320.66
CEG
+1.73%
42.95
HIMS
+2.30%
98.68
DLTR
-1.82%

FAQ

What Is the Insulet (PODD) Share Price Today?

The live Insulet share price today is 310.90.

What Stock Exchange Does Insulet (PODD) Trade On?

Insulet is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Ticker (Stock Symbol) for Insulet?

The stock symbol (also called a 'ticker') for Insulet is "PODD."

What Is the Current Insulet Market Cap?

As of today, Insulet market capitalisation is 21.92B.

What Is Insulet's (PODD) Earnings Per Share (TTM)?

The Insulet EPS 5.73 (Trailing Twelve Months).

When Is the Next Insulet Earnings Date?

Insulet's next earnings report will be released on 06 Aug 2025.

Is PODD a Buy or Sell From a Technical Analyst Perspective?

Based on today's Insulet moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Insulet Stock Split?

Insulet has split 0 times. (See the PODD stock split history page for full effective split date and price information.)

How Many Employees Does Insulet Have?

Insulet currently has 3900 employees.

What is the current trading status of Insulet (PODD)?

As of 25 Jun 2025, Insulet (PODD) is trading at a price of 310.90, with a previous close of 307.67. The stock has fluctuated within a day range of 304.13 to 315.49, while its 52-week range spans from 173.00 to 329.33.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.